Research graph
References from JNJ-79032421, a Novel Membrane-Restricted Mesothelin-Targeting T Cell–Engaging Bispecific Antibody for the Treatment of Mesothelin-Positive Cancers. Local targets link to admitted publications; unresolved targets remain external evidence.
Novel antibody therapeutics targeting mesothelin in solid tumors
10.2174/2212697x03666160218215744 · 2016 · External reference
Mesothelin: an immunotherapeutic target beyond solid tumors
10.3390/cancers14061550 · 2022 · External reference
Targeting mesothelin in cancer
10.1016/j.omto.2023.100756 · 2023 · External reference
Biology of mesothelin and clinical implications: a review of existing literature
10.14740/wjon1655 · 2023 · External reference
Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium
10.1002/ijc.2910500308 · 1992 · External reference
Mesothelin expression in human lung cancer
10.1158/1078-0432.ccr-06-2161 · 2007 · External reference
Application of mesothelin immunostaining in tumor diagnosis
10.1097/00000478-200311000-00003 · 2003 · External reference
Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma
10.18632/oncotarget.15814 · 2017 · External reference
Mesothelin expression in human tumors: a tissue microarray study on 12,679 tumors
10.3390/biomedicines9040397 · 2021 · External reference
Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding
10.1158/0008-5472.can-11-0466 · 2011 · External reference
Mesothelin variant 1 is released from tumor cells as a diagnostic marker
10.1158/1055-9965.epi-05-0334 · 2006 · External reference
Multiple proteases are involved in mesothelin shedding by cancer cells
10.1038/s42003-020-01464-5 · 2020 · External reference
Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
10.1016/j.tranon.2022.101440 · 2022 · External reference
Reduced shedding of surface mesothelin improves efficacy of mesothelin-targeting recombinant immunotoxins
10.1158/1535-7163.mct-15-0863 · 2016 · External reference
Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope
10.1073/pnas.2317283121 · 2024 · External reference
MSLN and CD3 binding agents and methods of use thereof. WO2024/089551Al International Application No. PCT/IB2023/060582
2023 · External reference
Unresolved reference
2011 · External reference
Data processing and analysis with the autoPROC toolbox
10.1107/s0907444911007773 · 2011 · External reference
PHENIX: a comprehensive Python-based system for macromolecular structure solution
10.1107/s0907444909052925 · 2010 · External reference
Features and development of Coot
10.1107/s0907444910007493 · 2010 · External reference
Phaser crystallographic software
10.1107/s0021889807021206 · 2007 · External reference
MolProbity: all-atom structure validation for macromolecular crystallography
10.1107/s0907444909042073 · 2010 · External reference
Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis
10.1016/j.medj.2022.09.007 · 2022 · External reference
Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer
10.1111/cas.12987 · 2016 · External reference
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
10.1136/thx.2006.068114 · 2007 · External reference
Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity
10.1172/jci.insight.186268 · 2024 · External reference
